Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
Mori J KrantzSebastian E DebusJudith HsiaManesh R PatelSonia S AnandMark R NehlerConnie N HessWarren H CapellTaylor BrackenMichael SzarekLajos MátyásDainis K KrievinsPatrice NaultStefan StefanovLloyd P HaskellScott D BerkowitzEva MuehlhoferWilliam R HiattRupert M BauersachsMarc P BonacaPublished in: European heart journal (2021)
Patients ≥75 years with PAD are at both heightened ischaemic and bleeding risk after LER. No excess harm with respect to major, intracranial or fatal bleeding was seen in older patients yet numerically greater absolute benefits were observed. This suggests that low-dose rivaroxaban combined with aspirin should be considered in PAD after LER regardless of age.
Keyphrases
- low dose
- atrial fibrillation
- peripheral artery disease
- high dose
- venous thromboembolism
- end stage renal disease
- ejection fraction
- pulmonary embolism
- chronic kidney disease
- newly diagnosed
- prognostic factors
- liver failure
- clinical trial
- cardiovascular events
- study protocol
- type diabetes
- respiratory failure
- phase iii
- open label
- coronary artery bypass grafting
- acute coronary syndrome
- patient reported outcomes
- drug induced
- extracorporeal membrane oxygenation
- optical coherence tomography
- mechanical ventilation
- anti inflammatory drugs